[The practical value of breast cancer molecular classification]

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Breast cancer is a leading cause of cancer death in women, characterized by significant clinical heterogeneity.
• Existing prognostic factors like lymph node status and tumor size are insufficient for accurate clinical outcome prediction.
• Molecular differences in tumors, despite histological similarity, are believed to drive divergent clinical behaviors.

Discussion:

• Microarray expression profiling identifies distinct molecular subtypes of breast cancer (e.g., luminal A, luminal B, basal-like, HER2).
• These molecular subtypes exhibit different prognoses and sensitivities to preoperative chemotherapy.
• Molecular classification provides a more refined understanding of breast cancer heterogeneity than traditional methods.

Key Insights:

• Molecular subtypes of breast cancer are crucial for predicting prognosis and treatment response.
• Traditional prognostic factors are inadequate for precise clinical outcome prediction.
• Understanding molecular differences is key to addressing breast cancer's clinical heterogeneity.

Outlook:

• Development of novel, subtype-specific prevention and treatment strategies is essential.
• Further research into the genetic and molecular underpinnings of breast cancer subtypes is warranted.
• Personalized medicine approaches based on molecular profiling will likely transform breast cancer care.